10x Genomics, Cleveland Clinic Team Up on Bladder Cancer Diagnostics
TXG collaborates with the Cleveland Clinic to advance bladder cancer diagnostics using Flex Apex, Xenium and potentially Atera.
TXG - 10x Genomics, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$26.00
DETAILS
HIGH:
$40.00
LOW:
$17.00
MEDIAN:
$22.00
CONSENSUS:
$26.00
DOWNSIDE:
38.97%
Stock News
Torex Gold Announces Results of Its 2026 Meeting of Shareholders
Meeting marks formal transition of Andrew Snowden into role of President and CEO Toronto, Ontario--(Newsfile Corp. - June 17, 2026) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) (OTCQX: TORXF) announces the results of its 2026 annual and special meeting of shareholders (the "Meeting") held virtually today. The Meeting marked the retirement of Jody Kuzenko and the formal appointment of Andrew Snowden as President and CEO of the Company.
Torex Gold Resources Inc. (TXG:CA) Shareholder/Analyst Call Prepared Remarks Transcript
Torex Gold Resources Inc. (TXG:CA) Shareholder/Analyst Call Prepared Remarks Transcript
10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer
Collaboration aims to identify biomarkers predictive of antibody-drug conjugate (ADC) treatment response using 10x's single cell and spatial platforms PLEASANTON, Calif., June 17, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a research collaboration with Cleveland Clinic, a nonprofit multispecialty academic medical center that integrates clinical care with research and education, to advance research in novel diagnostics for bladder cancer.
TXG Gains From Proteintech Deal, Expands Multiomics Capabilities
10x Genomics stock rises after acquiring Proteintech Genomics, adding high-plex proteomics tools that strengthen multiomics research and support platform adoption.
10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group
Acquisition Expands 10x Genomics' Capabilities in Proteomics PLEASANTON, Calif., June 9, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced the acquisition of Proteintech Genomics, a division within Proteintech Group, a company specializing in developing high-plex proteomic solutions for single cell and spatial applications on 10x platforms.
10x Genomics, Inc. (TXG) Shareholder/Analyst Call Prepared Remarks Transcript
10x Genomics, Inc. (TXG) Shareholder/Analyst Call Prepared Remarks Transcript
10x Genomics CEO Sells Nearly 30,000 Shares. Here's What That Means for Investors.
10x Genomics, a leader in single cell and spatial genomics tools, reported a notable insider sale amid ongoing sector innovation.
10x Genomics, Inc. (TXG) Presents at Bank of America Global Healthcare Conference 2026 Transcript
10x Genomics, Inc. (TXG) Presents at Bank of America Global Healthcare Conference 2026 Transcript
This $4 Million Bet Shows Growing Confidence in 10x Genomics as Stock Surges 116%
10x Genomics provides advanced tools for single cell and spatial biology research, serving academic and biopharma institutions worldwide.
Torex Gold Resources Inc. (TXG:CA) Q1 2026 Earnings Call Transcript
Torex Gold Resources Inc. (TXG:CA) Q1 2026 Earnings Call Transcript
10x Genomics Q1 Earnings Call Highlights
10x Genomics NASDAQ: TXG reported a first-quarter revenue increase excluding prior-year settlement revenue and used its earnings call to emphasize the launch of Atera, a new spatial biology instrument platform that management described as the most significant product introduction in the company's history.
10x Genomics Q1 Earnings & Revenues Beat Estimates, Gross Margin Up
TXG beats Q1 estimates as consumables growth, margin expansion and lower operating costs narrow losses year over year.
10x Genomics, Inc. (TXG) Q1 2026 Earnings Call Transcript
10x Genomics, Inc. (TXG) Q1 2026 Earnings Call Transcript
10x Genomics (TXG) Reports Q1 Loss, Beats Revenue Estimates
10x Genomics (TXG) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.36 per share a year ago.
10x Genomics (TXG) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
10x Genomics Reports First Quarter 2026 Financial Results
PLEASANTON, Calif., May 7, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2026.
10x Genomics (TXG) Expected to Beat Earnings Estimates: Should You Buy?
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
10x Genomics to Participate in the BofA Securities 2026 Healthcare Conference
PLEASANTON, Calif., April 29, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the BofA Securities 2026 Healthcare Conference on Wednesday, May 13, at 5:00 p.m.
LiquidCell Dx Appoints Former Foundation Medicine, 10x Genomics and IDT Leader Mirna Jarosz as Chief Executive Officer; Names Former Foundation Medicine Chief Medical Officer Vincent A. Miller, MD, Senior Strategic Advisor
SAN CARLOS, Calif.--(BUSINESS WIRE)--LiquidCell Dx, a precision diagnostics company building a blood-based platform for tumor microenvironment profiling, today announced the appointment of Mirna Jarosz as Chief Executive Officer and Vincent A. Miller, MD, as Senior Strategic Advisor. The appointments add operating, commercialization and clinical leadership as the company advances its platform and prepares for the next stage of growth. Comprehensive genomic profiling changed oncology by making t.
Price Targets
10x Genomics price target raised to $37 from $22 at Morgan Stanley
$37.00
(was $37.47)
Kallum Titchmarsh
·
Morgan Stanley
10x Genomics price target raised to $40 from $30 at Barclays
$40.00
(was $31.87)
Luke Sergott
·
Barclays
10x Genomics price target raised to $22 from $20 at Morgan Stanley
$22.00
(was $20.60)
Morgan Stanley
10x Genomics price target raised to $30 from $22 at Barclays
$30.00
(was $23.58)
Barclays
10X Genomics (TXG) PT Raised to $25 at Stifel on Solid New Product Adoption
$25.00
(was $22.38)
Daniel Arias
·
Stifel Nicolaus
10x Genomics price target raised to $20 from $14 at UBS
$20.00
(was $19.19)
UBS
10x Genomics price target raised to $17 from $16 at Deutsche Bank
$17.00
(was $19.40)
Deutsche Bank
10x Genomics price target raised to $20 from $15 at Stifel
$20.00
(was $17.51)
Stifel Nicolaus
10x Genomics price target raised to $22 from $20 at Canaccord
$22.00
(was $17.51)
Kyle Mikson
·
Canaccord Genuity
10X Genomics (TXG) PT Raised to $21 at BofA Securities
$21.00
(was $20.46)
Needham
10x Genomics price target raised to $20 from $19 at Canaccord
$20.00
(was $16.05)
Canaccord Genuity
10x Genomics price target raised to $22 from $17 at Barclays
$22.00
(was $15.45)
Barclays
10x Genomics assumed at Equal Weight from Overweight at Morgan Stanley
$20.00
(was $18.08)
Kallum Titchmarsh
·
Morgan Stanley
10x Genomics price target raised to $16 from $15 at Canaccord
$16.00
(was $12.39)
Kyle Mikson
·
Canaccord Genuity
10x Genomics price target raised to $13 from $12 at UBS
$13.00
(was $12.03)
Dan Leonard
·
UBS
10x Genomics price target raised to $14 from $10 at Deutsche Bank
$14.00
(was $12.29)
Justin Bowers
·
Deutsche Bank
10x Genomics price target lowered to $46 from $50 at Morgan Stanley
$46.00
(was $19.65)
Tejas Savant
·
Morgan Stanley
10x Genomics price target lowered to $32 from $50 at Canaccord
$32.00
(was $18.11)
Kyle Mikson
·
Canaccord Genuity
Deutsche downgrades 10x Genomics on demand erosion from competition
$25.00
(was $18.25)
Justin Bowers
·
Deutsche Bank
10x Genomics price target lowered to $24 from $36 at Barclays
$24.00
(was $19.85)
Luke Sergott
·
Barclays